Respiratory Failure clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • Revefenacin in Acute Respiratory Insufficiency in COPD

    open to eligible people ages 40 years and up

    RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

    Los Angeles, California and other locations

Our lead scientists for Respiratory Failure research studies include .

Last updated: